Is Agenus Stock a Hold Amid Valuation and Funding Risks?

AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.
Business Wire

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational ...

AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC

Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.
Forbes

1,000 Firms Out, 65 In: What’s Happening To The 8(a) Program?

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The Small Business Administration’s 8(a) Business Development Program has long served as one ...